Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.
Si-Bone, Inc. (SIBN) is a leader in minimally invasive surgical solutions for sacroiliac joint disorders, pioneering orthopedic innovations since its founding. This news hub provides investors and healthcare professionals with essential updates on the company's progress in medical device development and market expansion.
Comprehensive SIBN Coverage: Access official press releases and third-party analysis covering regulatory milestones, quarterly earnings, product launches (including iFuse System updates), clinical trial results, and strategic partnerships. Our curated feed eliminates speculation to deliver actionable information about this NASDAQ-listed innovator.
Strategic Insights: Track SIBN's advancements in sacroiliac joint fusion technology alongside broader industry trends in orthopedic devices. Discover how patented titanium implants and FDA-cleared systems position the company within competitive medical sectors.
Bookmark this page for real-time updates on SIBN's financial performance, surgical innovation developments, and leadership in addressing underdiagnosed pelvic health conditions through clinically validated solutions.
SANTA CLARA, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- SI-BONE, a leader in musculoskeletal disorder solutions, will participate in the 2023 Bank of America Merrill Lynch Global Healthcare Conference. The event features a management fireside chat on May 9, 2023, at 1:55 p.m. Eastern Time. A live webcast will be accessible via the company's website with a 90-day post-event archive available for replay.
SI-BONE, known for the iFuse Implant System, has pioneered minimally invasive surgical treatments for SI joint disorders since 2009. With nearly 80,000 procedures performed by over 3,000 surgeons, SI-BONE enjoys wide insurance coverage for these treatments. This position enables continued advancements in clinical research and the commercialization of new surgical solutions for pelvic disorders.
SI-BONE, Inc. (Nasdaq: SIBN), a leader in surgical solutions for musculoskeletal disorders, will report its Q1 2023 financial results on May 1, 2023, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET. Interested investors can register for the call through the provided link. The company has established a strong market position with over 80,000 SI joint fusion procedures performed using its iFuse Implant System, backed by extensive research and insurance coverage. SI-BONE continues to innovate in clinical applications and expand its offerings for sacropelvic conditions.
FAQ
What is the current stock price of Si-Bone (SIBN)?
What is the market cap of Si-Bone (SIBN)?
